SPY337.46-8.32 -2.41%
DIA275.21-8.13 -2.87%
IXIC11,286.61-261.68 -2.27%

Interpace Biosciences Says Audit Committee Investigation Finds Billing And Compliance Complaints Unsubstantiated

PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ:IDXG) announced today that the Audit Committee of the Board of Directors has

· 10/14/2020 06:33

PARSIPPANY, NJ, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ:IDXG) announced today that the Audit Committee of the Board of Directors has completed an independent investigation into complaints of certain employment and billing and compliance matters and concluded that the allegations made in the complaints are unsubstantiated and that there was no evidence of any illegal acts.

As set forth in the Company’s Notification of Late Filing on Form 12b-25 filing announcing the Company’s inability to timely file its Form 10-Q for the quarter ended June 30, 2020, in July 2020, the Company received letters from employees, one of whom has left the Company’s employ, concerning certain employment and billing and compliance matters. In response, the Company informed its Audit Committee and Regulatory Compliance Committee as well as its independent registered public accounting firm. The Audit Committee commenced an investigation of these matters with the assistance of independent counsel and advisors thereto. The Audit Committee concluded that the allegations were not substantiated and that there was no evidence of any illegal acts.